Evidence-based guideline for red cell, platelet, plasma, and cryoprecipitate transfusion, massive transfusion protocols, transfusion reactions, and patient blood management in the critically ill.
A comprehensive, evidence-based clinical guideline for red blood cell, platelet, plasma, and cryoprecipitate transfusion in the critically ill adult patient. This resource synthesizes recommendations from the major international transfusion medicine professional societies, critical care consensus groups, hematology expert panels, and blood management organizations into a single integrated reference for intensivists, hematologists, transfusion medicine physicians, anesthesiologists, surgeons, and advanced practice providers who manage blood product therapy in acute and critical care settings.1 2 3 4 5 6 7
Blood product transfusion is among the most common therapeutic interventions in the intensive care unit, with approximately 40–50% of ICU patients receiving at least one red blood cell transfusion during their stay. Over the past two decades, a series of landmark randomized controlled trials have fundamentally shifted transfusion practice from liberal to restrictive strategies, demonstrating that lower hemoglobin thresholds are safe — and in many cases superior — across a broad range of critically ill populations. Simultaneously, advances in massive transfusion protocols, viscoelastic point-of-care testing, and patient blood management programs have improved outcomes in hemorrhagic shock, reduced unnecessary transfusions, and minimized transfusion-related adverse events including transfusion-related acute lung injury and transfusion-associated circulatory overload.
This guideline covers the complete spectrum of transfusion practice: evidence-based thresholds for each blood component, massive transfusion protocols with fixed-ratio and goal-directed strategies, recognition and management of all transfusion reactions, special population considerations, and patient blood management principles.
Contents:
| Part | Title | Coverage |
|---|---|---|
| Part 1 | Red Blood Cell Transfusion | Restrictive vs liberal strategy evidence (landmark trials); recommended hemoglobin thresholds by clinical scenario; physiologic transfusion triggers; single-unit transfusion policy; expected hemoglobin rise; ordering, compatibility, and crossmatch; storage lesion and age of blood; leukoreduction and irradiation |
| Part 2 | Platelet, Plasma & Cryoprecipitate Transfusion | Platelet transfusion thresholds and dosing; platelet refractoriness evaluation and management; plasma (FFP/FP24/thawed plasma) indications and dosing; warfarin reversal with PCC vs FFP; cryoprecipitate and fibrinogen concentrate indications and dosing; special considerations (HIT, TTP, ITP, DIC) |
| Part 3 | Massive Transfusion & Hemorrhage Management | MTP activation criteria; fixed-ratio transfusion (1:1:1); TEG/ROTEM viscoelastic testing — parameters and interpretation; damage control resuscitation; permissive hypotension; tranexamic acid (TXA) dosing and evidence; calcium replacement; temperature management; MTP deactivation; trauma, obstetric, and GI hemorrhage protocols |
| Part 4 | Transfusion Reactions, Safety & Patient Blood Management | Acute hemolytic reactions; febrile non-hemolytic reactions; allergic and anaphylactic reactions; TRALI definition and management; TACO recognition and management; TRALI vs TACO differential table; bacterial contamination; delayed hemolytic reactions; reporting requirements; patient blood management (preoperative anemia optimization, cell salvage, antifibrinolytics, POC-guided transfusion); special populations; quality metrics |
Carson JL, Guyatt G, Heddle NM, et al. “Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage.” JAMA. 2016;316(19):2025-2035. DOI: 10.1001/jama.2016.9185 ↩︎
Hébert PC, Wells G, Blajchman MA, et al. “A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical Care.” N Engl J Med. 1999;340(6):409-417. DOI: 10.1056/NEJM199902113400601 ↩︎
Holst LB, Haase N, Wetterslev J, et al. “Lower versus Higher Hemoglobin Threshold for Transfusion in Septic Shock.” N Engl J Med. 2014;371(15):1381-1391. DOI: 10.1056/NEJMoa1406617 ↩︎
Holcomb JB, Tilley BC, Baraniuk S, et al. “Transfusion of Plasma, Platelets, and Red Blood Cells in a 1:1:1 vs a 1:1:2 Ratio and Mortality in Patients with Severe Trauma: The PROPPR Randomized Clinical Trial.” JAMA. 2015;313(5):471-482. DOI: 10.1001/jama.2015.12 ↩︎
CRASH-2 trial collaborators. “Effects of Tranexamic Acid on Death, Vascular Occlusive Events and Blood Transfusion in Trauma Patients with Significant Haemorrhage (CRASH-2): A Randomised, Placebo-Controlled Trial.” Lancet. 2010;376(9734):23-32. DOI: 10.1016/S0140-6736(10)60835-5 ↩︎
Kaufman RM, Djulbegovic B, Gernsheimer T, et al. “Platelet Transfusion: A Clinical Practice Guideline From the AABB.” Ann Intern Med. 2015;162(3):205-213. DOI: 10.7326/M14-1589 ↩︎
Napolitano LM, Kurek S, Luchette FA, et al. “Clinical Practice Guideline: Red Blood Cell Transfusion in Adult Trauma and Critical Care.” Crit Care Med. 2009;37(12):3124-3157. DOI: 10.1097/CCM.0b013e3181b39f1b ↩︎
Recognition and management of all transfusion reactions (hemolytic, FNHTR, allergic, TRALI, TACO), TRALI vs TACO differential table, reporting requirements, patient blood management (PBM), special populations including Jehovah's Witness patients, and quality metrics.
Massive transfusion protocol activation, fixed-ratio transfusion (1:1:1 per PROPPR), TEG/ROTEM viscoelastic testing and interpretation, damage control resuscitation, TXA (CRASH-2), calcium replacement, permissive hypotension, and hemorrhage management in trauma, obstetric, and GI bleeding.
Evidence-based indications, thresholds, and dosing for platelet, plasma (FFP/FP24), and cryoprecipitate/fibrinogen concentrate transfusion, including platelet refractoriness, warfarin reversal, and special considerations for HIT, TTP, ITP, and DIC.
Evidence-based hemoglobin thresholds for RBC transfusion in the critically ill, landmark trial evidence (TRICC, TRISS, FOCUS, TITRe2, TRICS-III), physiologic triggers, single-unit policy, compatibility testing, and storage considerations.